TargetMol

XR9051 Hydrochloride

Product Code:
 
TAR-T29169
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T29169-5mg5mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29169-50mg50mg£1,982.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29169-100mg100mg£2,560.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
XR9051 Hydrochloride, a potent modulator of P-glycoprotein-mediated multidrug resistance (MDR), inhibits the binding of cytotoxics to P-glycoprotein.
CAS:
180422-22-4
Formula:
C39H38N4O5
Molecular Weight:
642.756
Purity:
0.98
SMILES:
COc1cc2CCN(CCc3ccc(NC(=O)c4cccc(C=c5/[nH]c(=O)c(=Cc6ccccc6)n(C)c5=O)c4)cc3)Cc2cc1OC

References

1. Dale IL, Tuffley W, Callaghan R, Holmes JA, Martin K, Luscombe M, Mistry P, Ryder H, Stewart AJ, Charlton P, Twentyman PR, Bevan P. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer. 1998 Oct;78(7):885-92. PubMed PMID: 9764579; PubMed Central PMCID: PMC2063130. 2. Mistry P, Plumb J, Eccles S, Watson S, Dale I, Ryder H, Box G, Charlton P, Templeton D, Bevan PB. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer. 1999 Apr;79(11-12):1672-8. PubMed PMID: 10206276; PubMed Central PMCID: PMC2362811. 3. Minuesa G, Arimany-Nardi C, Erkizia I, Cede?o S, Molt? J, Clotet B, Pastor-Anglada M, Martinez-Picado J. P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load. J Antimicrob Chemother. 2016 Oct;71(10):2782-92. doi: 10.1093/jac/dkw215. Epub 2016 Jun 21. PubMed PMID: 27334660; PubMed Central PMCID: PMC5031918. 4. Wheeler R, Neo SY, Chew J, Hladky SB, Barrand MA. Use of membrane vesicles to investigate drug interactions with transporter proteins, P-glycoprotein and multidrug resistance-associated protein. Int J Clin Pharmacol Ther. 2000 Mar;38(3):122-9. PubMed PMID: 10739115.